Development and Clinical Application of Pneumococcal Vaccines

Streptococcus pneumoniae remains a leading global cause of morbidity and mortality, particularly affecting young children and older adults. While vaccination against pneumococcus has markedly reduced the disease burden worldwide, challenges such as serotype replacement, antibiotic resistance, and limited vaccine uptake persist. To address these issues, this review summarizes the mechanisms of vaccine-induced immunity, the development of diverse vaccine platforms—including polysaccharide, conjugate, and protein-based vaccines—as well as recent innovations such as mRNA and mucosal vaccines. Clinical and epidemiological data are integrated to evaluate the effectiveness of current strategies and the growing requirement for personalized, region-specific, and cost-effective vaccination approaches. We further highlight the ongoing challenges, including vaccine design optimization, low coverage rates in vulnerable populations, and market competition, emphasizing the critical need for enhanced surveillance and policy support to advance global pneumococcal disease prevention efforts.